XPHOZAH

Growth

tenapanor

Ardelyx
NDAORALTABLET
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
0/100

Loss of Exclusivity

LOE Date
Nov 26, 2042
203 months away
Patent Expiry
Nov 26, 2042
Exclusivity Expiry
Oct 17, 2026

Patent Records (5)

Patent #ExpiryTypeUse Code
12016856
Dec 30, 2029
SubstanceProduct
—
8969377
Dec 30, 2029
SubstanceProduct
—
8541448
Aug 1, 2033
SubstanceProduct
—
10272079
Apr 10, 2034
U-381
10940146
Apr 10, 2034
U-381
Company
Ardelyx
Ardelyx
CA - Fremont
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers